D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Chemistry D-index 72 Citations 17,804 371 World Ranking 2230 National Ranking 848
Medicine D-index 76 Citations 19,164 247 World Ranking 11337 National Ranking 6030

Research.com Recognitions

Awards & Achievements

1993 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Enzyme
  • Organic chemistry
  • Biochemistry

Alexandros Makriyannis mainly focuses on Cannabinoid, Cannabinoid receptor, Pharmacology, Endocannabinoid system and Receptor. Alexandros Makriyannis combines subjects such as Agonist, Antagonist, Cannabinoid receptor type 2, Stereochemistry and Anandamide with his study of Cannabinoid. His research in Cannabinoid receptor intersects with topics in Endocrinology and Inverse agonist.

His Pharmacology research includes elements of AM251, Rimonabant, Hippocampal formation, Cannabinoid Receptor Agonists and In vivo. His work is dedicated to discovering how Endocannabinoid system, Fatty acid amide hydrolase are connected with Neuroprotection and other disciplines. His Receptor research includes themes of Inflammation, Neurochemical, Endogeny and Central nervous system.

His most cited work include:

  • Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors (1223 citations)
  • Functional role of high-affinity anandamide transport, as revealed by selective inhibition. (735 citations)
  • Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS (435 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cannabinoid, Cannabinoid receptor, Pharmacology, Stereochemistry and Endocannabinoid system. The Cannabinoid study combines topics in areas such as Agonist, Endocrinology, Antagonist and Cannabinoid receptor type 2. His Cannabinoid receptor research is multidisciplinary, incorporating elements of Neuroscience and Ligand.

His studies in Pharmacology integrate themes in fields like AM251, Cannabinoid receptor antagonist, Rimonabant, Inverse agonist and In vivo. His Stereochemistry study incorporates themes from Biological activity, Structure–activity relationship, Ring and Chemical synthesis. The various areas that Alexandros Makriyannis examines in his Endocannabinoid system study include Endogeny and Fatty acid amide hydrolase.

He most often published in these fields:

  • Cannabinoid (44.52%)
  • Cannabinoid receptor (40.10%)
  • Pharmacology (33.88%)

What were the highlights of his more recent work (between 2014-2021)?

  • Pharmacology (33.88%)
  • Cannabinoid (44.52%)
  • Cannabinoid receptor (40.10%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Pharmacology, Cannabinoid, Cannabinoid receptor, Endocannabinoid system and Receptor. His Pharmacology research is multidisciplinary, relying on both In vivo, Inverse agonist, Antagonist, Rimonabant and Nicotine. The concepts of his Cannabinoid study are interwoven with issues in Agonist and Antagonism.

His biological study spans a wide range of topics, including Neuropathic pain and Stereochemistry. His Cannabinoid receptor study combines topics in areas such as Endocrinology and Neuroscience. His study explores the link between Endocannabinoid system and topics such as Fatty acid amide hydrolase that cross with problems in Anandamide, URB597 and Neuroprotection.

Between 2014 and 2021, his most popular works were:

  • Crystal Structure of the Human Cannabinoid Receptor CB2. (310 citations)
  • Crystal structures of agonist-bound human cannabinoid receptor CB1 (209 citations)
  • A new antibiotic selectively kills Gram-negative pathogens (105 citations)

In his most recent research, the most cited papers focused on:

  • Enzyme
  • Organic chemistry
  • Biochemistry

Alexandros Makriyannis mainly investigates Pharmacology, Endocannabinoid system, Cannabinoid, Cannabinoid receptor and Rimonabant. His study in Pharmacology is interdisciplinary in nature, drawing from both Cannabinoid receptor type 1, Fatty acid amide hydrolase, Opioid and Cannabinoid receptor type 2. His research integrates issues of Endocrinology, Arachidonic acid and Linoleic acid in his study of Endocannabinoid system.

Alexandros Makriyannis is investigating Cannabinoid receptor as part of his Receptor and Agonist and Cannabinoid receptor study. Alexandros Makriyannis works mostly in the field of Receptor, limiting it down to concerns involving Signal transduction and, occasionally, HEK 293 cells. The study incorporates disciplines such as Cannabinoid receptor antagonist, Inverse agonist and Nicotine in addition to Rimonabant.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors

Marja D. Van Sickle;Marnie Duncan;Philip J. Kingsley;Abdeslam Mouihate.
Science (2005)

1609 Citations

Functional role of high-affinity anandamide transport, as revealed by selective inhibition.

M. Beltramo;N. Stella;A. Calignano;S. Y. Lin.
Science (1997)

1008 Citations

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.

Mohab M. Ibrahim;Frank Porreca;Josephine Lai;Phillip J. Albrecht.
Proceedings of the National Academy of Sciences of the United States of America (2005)

580 Citations

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS

Mohab M. Ibrahim;Hongfeng Deng;Alexander Zvonok;Debra A. Cockayne.
Proceedings of the National Academy of Sciences of the United States of America (2003)

555 Citations

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.

Ruoxi Lan;Qian Liu;Pusheng Fan;Sonyuan Lin.
Journal of Medicinal Chemistry (1999)

544 Citations

CB2 cannabinoid receptor-mediated peripheral antinociception.

T.Philip Malan;Mohab M. Ibrahim;Hongfeng Deng;Qian Liu.
Pain (2001)

488 Citations

Endocannabinoids control spasticity in a multiple sclerosis model

D Baker;G Pryce;J L Croxford;P Brown.
The FASEB Journal (2001)

467 Citations

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

Joseph Tam;V. Kiran Vemuri;Jie Liu;Sándor Bátkai.
Journal of Clinical Investigation (2010)

452 Citations

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

Sándor Bátkai;Zoltán Járai;Jens A. Wagner;Sravan K. Goparaju.
Nature Medicine (2001)

434 Citations

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.

Ruth A Ross;Heather C Brockie;Lesley A Stevenson;Vicki L Murphy.
British Journal of Pharmacology (1999)

430 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Alexandros Makriyannis

Vincenzo Di Marzo

Vincenzo Di Marzo

Université Laval

Publications: 210

Daniele Piomelli

Daniele Piomelli

University of California, Irvine

Publications: 174

Mauro Maccarrone

Mauro Maccarrone

University of L'Aquila

Publications: 142

Roger G. Pertwee

Roger G. Pertwee

University of Aberdeen

Publications: 113

Benjamin F. Cravatt

Benjamin F. Cravatt

Scripps Research Institute

Publications: 101

Ken Mackie

Ken Mackie

Indiana University

Publications: 91

George Kunos

George Kunos

National Institutes of Health

Publications: 85

Aron H. Lichtman

Aron H. Lichtman

Virginia Commonwealth University

Publications: 78

Raphael Mechoulam

Raphael Mechoulam

Hebrew University of Jerusalem

Publications: 73

Cecilia J. Hillard

Cecilia J. Hillard

Medical College of Wisconsin

Publications: 67

Mercè Correa

Mercè Correa

Jaume I University

Publications: 65

Pal Pacher

Pal Pacher

National Institutes of Health

Publications: 59

Matthew N. Hill

Matthew N. Hill

University of Calgary

Publications: 56

Beat Lutz

Beat Lutz

Johannes Gutenberg University of Mainz

Publications: 53

John D. Salamone

John D. Salamone

University of Connecticut

Publications: 52

Billy R. Martin

Billy R. Martin

Virginia Commonwealth University

Publications: 51

Trending Scientists

Joseph Y. Lo

Joseph Y. Lo

Duke University

Chuanfang Zhang

Chuanfang Zhang

Swiss Federal Laboratories for Materials Science and Technology

Jennifer A. Field

Jennifer A. Field

Oregon State University

Elaine A. Ostrander

Elaine A. Ostrander

National Institutes of Health

Merete Fredholm

Merete Fredholm

University of Copenhagen

Frank Kunst

Frank Kunst

Institut Pasteur

Huai Jen Yang

Huai Jen Yang

National Cheng Kung University

Marshall Schminke

Marshall Schminke

University of Central Florida

Gregory R. Maio

Gregory R. Maio

University of Bath

Neil H. Bander

Neil H. Bander

Cornell University

Hervé Fernandez

Hervé Fernandez

Inserm : Institut national de la santé et de la recherche médicale

Jonathan G. Goldin

Jonathan G. Goldin

University of California, Los Angeles

Qingyue Meng

Qingyue Meng

Peking University

Joern H. Block

Joern H. Block

University of Trier

Paul K. Huth

Paul K. Huth

University of Maryland, College Park

Something went wrong. Please try again later.